NEW YORK, April 18, 2017 /PRNewswire/ --
When it comes to cancer- a disease that has been referred to as the 'modern plague' - any positive developments are good news indeed. In the ongoing battle against cancer, companies like TapImmune, Inc. (NASDAQ: TPIV) (TPIV Profile), Anavex Life Sciences Corp.
There was both good and bad news in the United States Government's latest Annual Report to the Nation on the Status of Cancer(1), which covers the time period spanning 1975-2014. The good news: cancer death rates continue to decrease in men, women and children for all major ethnic groups; the overall rates of new cancers have decreased in men and stabilized in women; and five-year survival rates have improved for most-but not all-common types of cancer, including both early- and late-stage disease. The bad news: death rates have increased for liver, pancreas and brain cancers in men and for liver and uterine cancers in women.
Fewer bad tidings and many more good are the aim of various companies engaged in finding and developing new and innovative means of treating cancer.
Some exciting cancer therapy advancements come from TapImmune, Inc. (TPIV), a leading immuno-oncology company that provides pioneering T-cell vaccines and novel immunotherapy platforms. TapImmune's immunotherapies take the unique approach of targeting both metastatic disease and tumors. The primary cause of death among cancer patients is not the primary tumor but metastatic disease, or the spreading of cancer to untreatable areas of the body. TapImmune's therapies have advanced beyond the abilities of earlier vaccine approaches by treating both tumors and metastatic diseases, and TapImmune's work is further distinguished by its approach of activating a patient's own immune system in fighting cancer. While the idea of enlisting the body's immune system to combat cancer is not a new one, recent and dramatic breakthroughs by companies like TapImmune have brought this concept to the forefront in an exciting way.
TapImmune's next-generation technology is able to standalone as a powerful therapy or be combined with other immunotherapies. The company is currently developing two vaccines that merge proprietary peptide antigen sets designed to invoke both killer T-cell (CD8) and helper T-cell (CD4) immune responses against specific proteins present on the surface of most target tumor cells. The naturally processed antigens in these vaccines are derived from human immune responses that are recognized by over 85 percent of the population. This enables TapImmune to direct a uniquely strong and durable anti-tumor immune response across a broader patient population. Other companies in the oncology field lag far behind TapImmune, developing immune-modulating technologies that prompt only CD4 T-cell response, only CD8 T-cell response, or none at all.
The company is currently advancing its two clinical-stage T-cell vaccine candidates in multiple phase II and phase Ib/IIa clinical trials for treating ovarian and breast cancers, both of which are typically resistant to immunotherapies. Included are ovarian cancer programs that will benefit from FDA Fast Track and Orphan Disease Designation. TapImmune is collaborating with industry and clinical leaders like the Mayo Clinic, AstraZeneca and the Memorial Sloan Kettering Cancer Center.
Clinical-stage biopharmaceutical company Anavex Life Sciences (NASDAQ: AVXL) is engaged in developing differentiated therapeutics to treat a variety of diseases, including cancer. The company is exploring the approach of using sigma receptors as targets for therapeutics to combat disease. Anavex has found that when sigma receptors are bound by the appropriate ligands, they influence the function of multiple biochemical signals involved in pathogenesis, or the origin of disease. The company's pipeline includes compounds in varying stages of preclinical study for the treatment of melanoma, pancreatic cancer, prostate cancer, colon cancer and ovarian cancer.
Propanc Health Group (OTCQB: PPCH), a development-stage health care company, is focused on developing new and proprietary treatments for cancer patients who are suffering from solid tumors like pancreatic, ovarian and colorectal cancers. Working with scientific and oncology consultants, Propanc has developed a rational, composite formulation of anti-cancer compounds that work together to exert various effects designed to control or prevent the recurrence and spread of tumors. The company's leading products are variations on its novel formulation and involve or employ proenzymes. The company's long-term therapy is based on a pancreatic proenzyme formulation to suppress tumor recurrence and metastasis, while PRP, its lead candidate, controls cancer cell migration, impedes tumor blood vessel formation and triggers cell death.
Clinical-stage biopharmaceutical company Aquinox Pharmaceutical (NASDAQ: AQXP) is also focused on the discovery and development of targeted therapeutics in immuno-oncology disease areas. While the company's chief focus is currently anti-inflammatory product candidates, its longer-term strategy is to broaden development activities for its lead product candidate, AXQ-1125, for the treatment of cancer.
The approach of clinical-stage biopharmaceutical company Bellicum Pharmaceuticals (NASDAQ: BLCM) is developing novel stem cell transplant, TCR and CAR T cell therapies. Operating on the belief that cellular control is the key to safer, more effective cell therapies, the company's product candidates incorporate molecular switches that are designed to allow the activation or elimination of therapeutic cells within the body. The focus of Bellicum Pharmaceuticals is discovering and developing cellular immunotherapies for hematological cancers, solid tumors and orphan inherited blood diseases.
As advancements continue in the fight against cancer, these companies continue their efforts to develop new methods for combating the disease and increase instances of good news for cancer patients and their loved ones.
For more information on TapImmune visit: TapImmune, Inc. or http://www.Tapimmune.com
NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.
1. Cancer.gov: http://nnw.fm/9uSBp
Media Contact e-mail: FN Media Group, LLC firstname.lastname@example.org +1-(954)-345-0611
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All